MedTrace Logo

Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine

NCT07400003 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 519

Last updated 2026-02-10

No results posted yet for this study

Summary

This clinical trial included two parts, Part A and Part B. The goal of Part A is to evaluate the safety and preliminary immunogenicity of the lyophilized herpes zoster virus mRNA vaccine (HZ mRNA vaccine) in healthy populations aged 40 years and older. The goal of Part B is to select the optimal dosage and schedule in healthy populations aged 50 years and older to support next further study.

Conditions

  • Herpes Zoster
  • mRNA Vaccine

Interventions

BIOLOGICAL

Low-dose experimental vaccine

Lyophilized herpes zoster virus mRNA vaccine

BIOLOGICAL

High-dose experimental vaccine

Lyophilized herpes zoster virus mRNA vaccine

BIOLOGICAL

Active-controlled vaccine A

herpes zoster attenuated live vaccine, lyophilized

BIOLOGICAL

Active-controlled vaccine B

Shingrix®

OTHER

Placebo group

Saline

Sponsors & Collaborators

  • Sinovac Biotech Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Na Xie · Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-06
Primary Completion
2026-05-31
Completion
2027-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07400003 on ClinicalTrials.gov